ダウンロード数: 368

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
37_447.pdf983.98 kBAdobe PDF見る/開く
タイトル: 複雑性尿路感染症に対するCefpirome(CPR)とCeftazidime(CAZ)の比較検討
その他のタイトル: Comparative study of cefpirome and ceftazidime in complicated urinary tract infections
著者: 名出, 頼男  KAKEN_name
熊本, 悦明  KAKEN_name
広瀬, 崇興  KAKEN_name
土田, 正義  KAKEN_name
折笠, 精一  KAKEN_name
阿曽, 佳郎  KAKEN_name
押, 正也  KAKEN_name
町田, 豊平  KAKEN_name
鈴木, 恵三  KAKEN_name
河田, 幸道  KAKEN_name
坂, 義人  KAKEN_name
岡田, 謙一郎  KAKEN_name
守殿, 貞夫  KAKEN_name
荒川, 創一  KAKEN_name
大森, 弘之  KAKEN_name
公文, 裕巳  KAKEN_name
仁平, 寛巳  KAKEN_name
香川, 征  KAKEN_name
熊澤, 淨一  KAKEN_name
松本, 哲朗  KAKEN_name
江藤, 耕作  KAKEN_name
大井, 好忠  KAKEN_name
上野, 一恵  KAKEN_name
小川, 暢也  KAKEN_name
著者名の別形: Naide, Yorio
Kumamoto, Yoshiaki
Hirose, Takaoki
Tsuchida, Seigi
Orikasa, Seiichi
Aso, Yoshiro
Oshi, Masaya
Machida, Toyohei
Suzuki, Keizo
Kawada, Yukimichi
Ban, Yoshihito
Okada, Kenichiro
Kamidono, Sadao
Arakawa, Soichi
Oomori, Hiroyuki
Kumon, Hiromi
Nihira, Hiromi
Kagawa, Susumu
Kumazawa, Joichi
Matsumoto, Tetsuro
Eto, Kosaku
Ohi, Yoshitada
Ueno, Kazue
Ogawa, Nobuya
キーワード: Cefpirome
Complicated UTI
Comparative study
発行日: Apr-1991
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 37
号: 4
開始ページ: 447
終了ページ: 464
抄録: CPRは1回0.5 gまたは1.0 gを, CAZは1回1.0 gを1日2回, 点滴静注により5日間連続投与し, 臨床効果はUTI薬効評価基準により評価した.総投与症例530例中効果判定が可能であった症例はCPR 1日1 g投与群141例, CPR 1日2 g投与群136例, CAZ 1日2 g投与群140例であった.CPRは複雑性尿路感染症に対してCAZと同様に有用性の高い薬剤である
We carried out a randomized multi-center study comparing cefpirome (CPR) 0.5 g b.i.d. (1 g group), 1.0 g b.i.d. (2 g group) and ceftazidime (CAZ) 1.0 g b.i.d. (CAZ group) in the treatment of complicated urinary tract infections. Patients who were over 16 years old and had underlying urinary tract disease, with bacteriuria of more than 10(4) cells ml or more and pyuria of more than 5 WBCs/hpf (x 400) or more were randomly allocated to receive either 0.5 g of CPR, 1.0 g of CPR or 1.0 g of CAZ twice a day for 5 days by intravenous drip infusion. The overall clinical efficacy of the treatment was evaluated by the criteria of the Japanese UTI Committee as excellent, moderate or poor, on the basis of the changes in pyuria and bacteriuria. A total of 530 patients were treated. Of these, 141 patients in the 1 g group, 136 in the 2 g group, and 140 in the CAZ group were evaluable for clinical efficacy. No significant differences in background characteristics were observed among the treatment groups. The overall clinical efficacy rate of the 1 g group, the 2 g group and the CAZ group was 80.1%, 76.5% and 71.4%, respectively. The differences were not statistically significant. The overall bacteriological eradication rate of the 1 g group, the 2 g group and the CAZ group was 81.0%, 88.1% and 83.8%. The differences were not statistically significant either. Against the enterococcus group, however, eradication rates were higher significantly in the 1 g and 2 g groups than in the CAZ group. The incidence of adverse reactions was 2.2% in the 1 g group, 0.6% in the 2 g group and 2.9% in the CAZ group. Abnormal laboratory data after medication were observed in 10.8% of the 1 g group, 12.1% of the 2 g group and 10.2% of the CAZ group, the difference not being statistically significant. There were no serious untoward reactions to medication. From the results obtained in this study, we consider that CPR is at least as useful as CAZ in the treatment of complicated urinary tract infections.
URI: http://hdl.handle.net/2433/117148
PubMed ID: 1892004
出現コレクション:Vol.37 No.4

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。